Compare Amylx Pharmaceuticals Inc (AMLX) vs Remitly Global Inc (RELY) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

RELY stock trades at $24.42, down 5.82% over 24 hours, but maintains strong bullish technical signals with support at $24 and resistance at $26. The company demonstrates impressive fundamental momentum with Q2 2026 EPS of $0.93 beating expectations by 650% and revenue growth accelerating to 20% year-over-year. Recent initiatives include the Global Card launch and UAE licensing expansion, positioning for continued market share gains in the $800 billion remittance market.

With 92% analyst buy ratings and a $31 consensus price target implying 27% upside, RELY presents compelling growth potential. Key risks include execution challenges in new product launches and competitive pressure in digital payments. The stock's valuation at 17.56x P/E appears reasonable given 32.25% ROE and projected 16.85% net margins for 2026.